• Citer

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

par Praga, Claudio;Bergh, Jonas;Bliss, Judith M;Bonneterre, J;Cesana, Bruno;Coombes, Raoul Charles;Fargeot, Pierre;Folin, Annika;Fumoleau, Pierre;Giuliani, Rosa;Kerbrat, Pierre;Hery, Michel;Nilsson, Jonas;Onida, Francesco;Piccart-Gebhart, Martine ;Shepherd, L;Therasse, P.;Wils, J;Rogers, David
Référence Journal of clinical oncology, 23, 18, page (4179-4191)
Publication Publié, 2005-06

Article révisé par les pairs

• Détails
• Contenu

Résumé :

PURPOSE: We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). PATIENTS AND METHODS: The patients (N = 9,796) were observed from the start of adjuvant treatment (53,080 patient-years). Cases of AML or MDS (AML/MDS) were reported, with disease characteristics. Incidence and cumulative risk were compared for possible risk factors, for assigned regimens, and for administered cumulative doses of epirubicin and cyclophosphamide. RESULTS: In 7,110 patients treated with epirubicin-containing regimens (92% of whom also received cyclophosphamide), 8-year cumulative probability of AML/MDS was 0.55% (95% CI, 0.33% to 0.78%). The risk of developing AML/MDS increased in relation to planned epirubicin dose per cycle, planned epirubicin dose-intensity, and administered cumulative doses of epirubicin and cyclophosphamide. Patients with administered cumulative doses of both epirubicin and cyclophosphamide not exceeding those used in standard regimens (